Intercell & Romark combine to hit HCV
This article was originally published in Scrip
Executive Summary
Intercell, the Austrian vaccine technology company, has agreed to link up with Romark Laboratories, a Tampa, Florida-based company, to develop a combination hepatitis C treatment. The two companies plan to start a European Phase II trial of Intercell's investigation therapeutic HCV vaccine, IC41, in combination with Romark's antiviral thiazolide compound nitazoxanide, during the first half of 2011.